Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR C797G1
Osimertinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance	2	submitted	EID8078 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R+T790M transgene. Twenty of 49 mice treated with osimertinib developed treatment-resistant tum…

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Adenocarcinoma (MSK, 2021) luad_mskimpact_2021	Lung Adenocarcinoma	Ssm	183	186	98.4%

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated civic_curation

EGFR D761N2
Erlotinib + GefitinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5820 EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID5821 EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR D770_N771insNPG4
Cetuximab	Hematopoietic and Lymphoid Cell NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	—	submitted	EID4492 EGFR D770_N771insNPG insertion mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, NIH-3T3 cells … (full text at CIViC) PMID 16187797 · Greulich et al., 2005 · Open in CIViC	civic
Erlotinib	Hematopoietic and Lymphoid Cell NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	—	submitted	EID4491 EGFR D770_N771insNPG insertion mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, NIH-3T3 cells … (full text at CIViC) PMID 16187797 · Greulich et al., 2005 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4651 In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insNPG demonstrated reduced sensitivity to erlotinib treatment (IC50=2.139�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Afatinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID5947 Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation. Gefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic

EGFR D770_N771insSVD3
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID5941 2 patients with EGFR D770_N771insSVD positive lung adenocarcinoma were treated with erlotinib tyrosine kinase inhibitor as first line treatment. A 66 year old female never smoker had stable disease a… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	accepted	EID4275 In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4640 In an in vitro study, a MCF-7 cell line expressing D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment similar to MCF-7 cells expressing EGFR T790M (a known resistant mutation to E… (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC	civic

EGFR D770_P772dup6
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	1	submitted	EID12298 NIH3T3 cells transfected with the variant P772_H773insDNP, also known as D770_P772dup, results in focus formation. PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic
Afatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	submitted	EID12300 Sensitivity of a series of EGFR exon 20 insertion mutations to EGFR tyrosine kinase inhibitors was assessed using in vitro and in vivo mixed-all-nominated-in-one (MANO) method (PMID: 29141884) as well… (full text at CIViC) PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic
Gefitinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	submitted	EID12299 Sensitivity of a series of EGFR exon 20 insertion mutations to EGFR tyrosine kinase inhibitors was assessed using in vitro and in vivo mixed-all-nominated-in-one (MANO) method (PMID: 29141884) as well… (full text at CIViC) PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic
Mobocertinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	1	submitted	EID12303 Transformed Ba/F3 cells expressing p.P772_H773insDNP, also known as p.D770_P772dup, is sensitive (IC90 < 10nM) to Mobocertinib using the in vitro PrestoBlue cell viability assay. PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic
Osimertinib	Malignant NeoplasmALIAS	Predictive	D	Supports Reduced Sensitivity	3	submitted	EID12301 Sensitivity of a series of EGFR exon 20 insertion mutations to EGFR tyrosine kinase inhibitors was assessed using in vitro and in vivo mixed-all-nominated-in-one (MANO) method (PMID: 29141884) as well… (full text at CIViC) PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic
Poziotinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	1	submitted	EID12302 Transformed Ba/F3 cells expressing p.P772_H773insDNP, also known as p.D770_P772dup, is sensitive (IC90 < 10nM) to Poziotinib using the in vitro PrestoBlue cell viability assay. PMID 33395611 · Hirose et al., 2021 · Open in CIViC	civic

EGFR E114K4
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9585 Ba/F3 cells transfected with EGFR E114K had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9586 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR E114K. NIH-3T… (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Unaltered Function	2	accepted	EID9584 A functional screen of somatic mutations found in large-scale cancer data sets classified EGFR E114K as neutral, based on growth-factor independent growth in Ba/F3 and MCF10A cells, and consensus amon… (full text at CIViC) PMID 29533785 · Ng et al., 2018 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID9587 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR E114K showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic